Arbaclofen vs. Placebo in the Treatment of Children and Adolescents With ASD (ARBA)
Status:
Recruiting
Trial end date:
2022-05-15
Target enrollment:
Participant gender:
Summary
This study will examine the safety and efficacy of arbaclofen vs. placebo on social function
in children and adolescents with Autism Spectrum Disorder (ASD).
Phase:
Phase 2
Details
Lead Sponsor:
Evdokia Anagnostou
Collaborators:
Holland Bloorview Kids Rehabilitation Hospital McMaster University Queen's University St. Michael's Hospital, Toronto Unity Health Toronto University of Toronto University of Western Ontario, Canada